Nevada DMV data shows that 61% of SNAP recipients are overweight. The restrictions on candy and sweet drinks are connected to Medicaid cuts from President Trump's "One Big Beautiful Bill." The state ...

AbbVie Inc. ABBV shares are trading lower on Monday. The U.S. drug maker shared topline results from a Phase 1 study of ...

Structure Therapeutics (GPCR) stock jumped 10% after its GLP-1 pill aleniglipron posted 16.3% weight loss, outperforming Lilly and Novo's oral candidates.

The MAD portion of the study enrolled a total of 76 participants.

TIX100 is a specific, orally available TXNIP inhibitor originally developed for its beta-cell protective effects in diabetes. It has received FDA Investigational New Drug approval in diabetes and ...

Structure Therapeutics has touted the 16% weight loss—about 39 pounds—seen by aleniglipron as the best results yet for an oral GLP-1 drug, as the obesity biotech readies the candidate for phase 3. The ...

The reports of the two deaths of a man and a woman were made to the Medicines and Healthcare products Regulatory Agency (MHRA ...

More U.S. students are gaining weight, obesity is rising, but fewer are taking action to improve their health and build better daily habits.

Novo Nordisk's reports to the FDA spiked shortly after an inspection found the Ozempic producer ignored reports of deaths and potential side effects.

Novo Nordisk has multiple weight-loss drugs in various stages of development and approval, according to its R&D pipeline. These include, among others, monlunabant (phase 2); oral and subcutaneous ...

Learn about weighted as it applies to finance, describing how figures adjust based on component proportions and influence ...

By John Revill and Danny Callaghan KILCHBERG, Switzerland March 10 (Reuters) - Chocolate sales are rising faster among U.S. users of GLP-1 weight-loss drugs than in the rest of the population, Swiss ...